“LYMPHIR is an important new treatment option for the CTCL community, and its launch marks the beginning of a new chapter for ...

The global T-Cell lymphoma therapeutics market size was valued at US$ 2.3 Bn in 2024 and is projected to reach US$ 5.7 Bn by ...

CAR T-cell therapy, which transforms patients’ own immune cells into cancer-fighting warriors, has been extremely effective ...

The TERZO study evaluates Copiktra for relapsed or refractory nodal T-follicular helper cell lymphoma, lacking a standard treatment. The trial compares Copiktra with Gemzar or Bendeka, focusing on ...

Dave Coulier recently revealed another cancer diagnosis, mere months after recovering from Stage 3 non-Hodgkin’s lymphoma ...

Dave Coulier announced he is undergoing treatment for tongue cancer nearly eight months after he beat his battle with ...

Dave Coulier’s new tongue cancer diagnosis raises questions about whether it’s linked to his prior lymphoma. Experts explain the risks, causes, and why second primary cancers can occur.

Dave Coulier has been diagnosed with HPV-related tongue cancer, just months after going into remission from stage 3 ...

About 30 percent of all non-Hodgkin lymphoma diagnoses in the United States are DLBCL. Although it is an aggressive cancer that can spread quickly, it is treatable. These can be symptoms of many ...

Coulier, 66, was diagnosed with HPV-related oropharyngeal tongue cancer in October, he told TODAY.com in a phone interview.

The Full House alum shared that he's been diagnosed with tongue cancer, eight months after he confirmed he was cancer-free ...